Loading…
Lobbying Spend
—
Filings
81
Firms Hired
2
Active Period
2009–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Medical Foods and Formulas Access Act of 2025
2026 · third_quarter · Firm: HOLLAND & KNIGHT LLP
FY 2027 federal funding for DoD peer-reviewed medical research and the National Institutes of Health; Improvements in FDA rare disease New Drug Application review process; H.R. 5684 / S. 3304 - Medical Foods and Formulas Access Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5684
Medical Foods and Formulas Access Act of 2025
2026 · third_quarter · Firm: HOLLAND & KNIGHT LLP
FY 2027 federal funding for DoD peer-reviewed medical research and the National Institutes of Health; Improvements in FDA rare disease New Drug Application review process; H.R. 5684 / S. 3304 - Medical Foods and Formulas Access Act.
Client expense: — · Firm income: $20,000
Matched citations: S. 3304
Medical Foods and Formulas Access Act of 2025
2026 · second_quarter · Firm: HOLLAND & KNIGHT LLP
FY 2027 federal funding for DoD peer-reviewed medical research and the National Institutes of Health; Improvements in FDA rare disease New Drug Application review process; H.R. 5684 / S. 3304 - Medical Foods and Formulas Access Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5684
Medical Foods and Formulas Access Act of 2025
2026 · second_quarter · Firm: HOLLAND & KNIGHT LLP
FY 2027 federal funding for DoD peer-reviewed medical research and the National Institutes of Health; Improvements in FDA rare disease New Drug Application review process; H.R. 5684 / S. 3304 - Medical Foods and Formulas Access Act.
Client expense: — · Firm income: $20,000
Matched citations: S. 3304
Medical Foods and Formulas Access Act of 2025
2026 · first_quarter · Firm: HOLLAND & KNIGHT LLP
FY 2027 federal funding for DoD peer-reviewed medical research and the National Institutes of Health; Improvements in FDA rare disease New Drug Application review process; H.R. 5684 / S. 3304 - Medical Foods and Formulas Access Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5684
Medical Foods and Formulas Access Act of 2025
2026 · first_quarter · Firm: HOLLAND & KNIGHT LLP
FY 2027 federal funding for DoD peer-reviewed medical research and the National Institutes of Health; Improvements in FDA rare disease New Drug Application review process; H.R. 5684 / S. 3304 - Medical Foods and Formulas Access Act.
Client expense: — · Firm income: $20,000
Matched citations: S. 3304
Medical Nutrition Equity Act of 2019
2020 · fourth_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY21 Defense Appropriations Act (Title V - Health); FY21 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Medical Nutrition Equity Act of 2019
2020 · fourth_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY21 Defense Appropriations Act (Title V - Health); FY21 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Medical Nutrition Equity Act of 2019
2020 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY21 Defense Appropriations Act (Title V - Health); FY21 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Medical Nutrition Equity Act of 2019
2020 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY21 Defense Appropriations Act (Title V - Health); FY21 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Medical Nutrition Equity Act of 2019
2020 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY21 Defense Appropriations Act (Title V - Health); FY21 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Medical Nutrition Equity Act of 2019
2020 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY21 Defense Appropriations Act (Title V - Health); FY21 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Medical Nutrition Equity Act of 2019
2020 · first_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY21 Defense Appropriations Act (Title V - Health); FY21 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Medical Nutrition Equity Act of 2019
2020 · first_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY21 Defense Appropriations Act (Title V - Health); FY21 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Medical Nutrition Equity Act of 2019
2019 · fourth_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY20 Defense Appropriations Act (Title V - Health); FY20 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Medical Nutrition Equity Act of 2019
2019 · fourth_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY20 Defense Appropriations Act (Title V - Health); FY20 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Medical Nutrition Equity Act of 2019
2019 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY20 Defense Appropriations Act (Title V - Health); FY20 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Medical Nutrition Equity Act of 2019
2019 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY20 Defense Appropriations Act (Title V - Health); FY20 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Medical Nutrition Equity Act of 2019
2019 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY20 Defense Appropriations Act (Title V - Health); FY20 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Medical Nutrition Equity Act of 2019
2019 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY20 Defense Appropriations Act (Title V - Health); FY20 Labor-HHS Appropriations (NIH); Medical nutrition legislation; H.R. 2501, Medical Nutrition Equity Act of 2019.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2501
Advancing Access to Precision Medicine Act
2018 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY19 Defense Appropriations Act (Title V - Health); National Institutes of Health funding for mitochondrial research; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 5115, RARE Act of 2018.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5062
Promote federal funding for mitochondrial disease research, FY19 Defense Appropriations Act (Title V - Health); National Institutes of Health funding for mitochondrial research; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 5115, RARE Act of 2018.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5115
Advancing Access to Precision Medicine Act
2018 · second_quarter · Firm: HOLLAND & KNIGHT LLP
Promote federal funding for mitochondrial disease research, FY19 Defense Appropriations Act (Title V - Health); National Institutes of Health funding for mitochondrial research; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 5115, RARE Act of 2018.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5062
Promote federal funding for mitochondrial disease research, FY19 Defense Appropriations Act (Title V - Health); National Institutes of Health funding for mitochondrial research; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 5115, RARE Act of 2018.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5115
Mitochondrial Medicine Research and Treatment Enhancement Act
2010 · fourth_quarter · Firm: HOLLAND & KNIGHT LLP
Promote awareness and federal funding for mitochondrial disease research, including through FY11 Labor, HHS & Education Appropriations Act (Title II - National Institutes of Health), and authorization bill (H.R. 3502; S.2858).
Client expense: — · Firm income: $20,000
Matched citations: H.R. 3502
Source: Senate LDA